A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 961 participants.

Also called NCT03989232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 961 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03989232
  • EudraCT 2018-004529-96
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial The lancet. Diabetes & endocrinology, 2021-09 DOI, PubMed 34293304

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, Greece, Hungary, Japan, Poland, Puerto Rico, Slovakia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03989232. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-19 (actual); primary completion 2020-09-18 (actual). Results posted on 2021-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Acronym
SUSTAIN FORTE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03989232
Content hash
8107fa941823e13aac41a22c67c1f4395b6aa42cc186a9bbdb80d17dd8e393e5